The effect of oral immunization on corneal allograft survival.
The present study examined the potential of orally induced tolerance for preventing immunological rejection of corneal allografts. Orthotopic corneal allografts were transplanted from either C3H (MHC + multiple minor H-mismatched) or NZB (multiple minor H-mismatched only) donors to CB6F1 recipients on day 0. Tissue cultured corneal epithelial and endothelial cells from relevant donor strains were administered orally from day -14 to day -4 on a daily basis, The incidence of graft rejection, graft mean survival time (MST), and alloimmune responses, and the antigen specificity of induced tolerance were studied. Oral immunization induced a remarkable tolerance such that only 55% of the orally immunized hosts rejected their fully allogeneic corneal grafts (MST = 43 days) compared with 100% rejection (MST = 18 days) in normal controls. Likewise, rejection of MHC-matched, multiple minor H-mismatched corneal grafts fell from 80% in untreated controls to 36% in orally immunized hosts. Oral immunization was effective in desensitizing previously immunized hosts. Rejection of MHC-matched, multiple H minor-mismatched corneal allografts fell from 93% in preimmune, unfed hosts to 36% in preimmune, orally tolerized mice. Thus, oral immunization is a safe and effective method for desensitizing high-risk, preimmune hosts and promoting corneal allograft survival.
He
Y G
YG
Department of Ophthalmology, University of Texas Southwestern Medical Center at Dallas, Texas 75235-057, USA.
Mellon
J
J
Niederkorn
J Y
JY
D000284:Administration, Oral; D000818:Animals; D003315:Cornea / Q000166:cytology / Q000276:immunology*; D016039:Corneal Transplantation / Q000276:immunology*; D004848:Epithelium / Q000276:immunology / Q000637:transplantation; D000939:Epitopes; D005260:Female; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D006085:Graft Survival / Q000276:immunology*; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007114:Immunization; D007165:Immunosuppression Therapy / Q000379:methods*; D015994:Incidence; D007518:Isoantibodies / Q000096:biosynthesis; D007519:Isoantigens / Q000627:therapeutic use; D008285:Major Histocompatibility Complex / Q000276:immunology; D051379:Mice; D008809:Mice, Inbred C3H; D008814:Mice, Inbred NZB; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D013997:Time Factors; D014184:Transplantation, Homologous / Q000276:immunology
D000939:Epitopes; D007518:Isoantibodies; D007519:Isoantigens